Pieter van der Meijden

HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US.

Gynesonics, Inc. provides medical devices for women's health. It offers VizAblate System for the transcervical treatment of symptomatic uterine fibroids under intrauterine ultrasound guidance. The company was founded by Jessica grossman in 2005 and is headquartered in Redwood City, CA.

PrimaGen Holding BV designs and develops molecular diagnostic tests. The firm conducts tests in the fields of mitochondrial toxicity, drug development toxicology screening, HIV monitoring, DFS paper technology, oncology and virus discovery. It also develops in monitoring toxic side effects of antiviral medication and for diagnosing and monitoring certain forms of cancer. The company was founded in November 2001 and is headquartered in Amsterdam, the Netherlands.

CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany.

Part of Forbion Capital Partners Management Holding BV, the venture capital firm, Forbion Co-Investment II Coöperatief UA, is based in Naarden, Netherlands. Forbion Co-Investment II Coöperatief UA operates as a venture capital firm. The Dutch company was founded in 2000 by Bart Bergstein, Hugo Alexander Slootweg, Martien van Osch.

Symbiomix Therapeutics LLC develops medicines for women’s health infections and related diseases. It offers SYM-1219, a drug that contains secnidazole that facilitate administration as a single-dose oral therapy for various women's health infections including bacterial vaginosis. The company was founded by Jack Roberts, Steve Pomerantz and Joseph L. Amprey III in 2012 and is headquartered in Newark, NJ.

Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto.

Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands.

Discus Dental LLC develops, manufactures and distributes dental products such as tooth whitening, oral hygiene, preventatives, and restoratives. The company was co-founded by William Dorfman and Robert Hayman on December 7, 1990 and is headquartered in Culver City, CA.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

CardiacAssist, Inc. develops, manufactures and markets medical devices. The firm’s products include TandemLife Kit, TandemHeart Kit, TandemLung Kit, ProtekDuo Kit and educational videos. The company was founded by John C. Marous, Jr. and George J. Magovern in 1996 and is headquartered in Pittsburgh, PA.

Licentec provides evaluation of technology, patents, licensing, and IP management services. It offers support services to universities, knowledge institutions, companies, venture capitalists, and entrepreneurs in the commercialization of technology. The company was founded in 1978 and is headquartered in Bilthoven, the Netherlands

ING Bank NV (Broker) (ING Bank-Broker) is the broker-dealer division of ING Bank NV, an investment bank headquartered in Amsterdam, Netherlands. It is a wholly-owned subsidiary of ING Groep N.V. (AMS: INGA; NYSE: ING), a Dutch multinational banking and financial services corporation. The firm was founded in 1991 through the merger of Nationale-Nederlanden and NMB Postbank Groep. ING Bank-Broker provides brokerage services to institutions, large corporations, and medium-sized companies.

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.

The Royal Netherlands Academy of Arts & Sciences provides research services in the field of science and art. The private company is based in Amsterdam, Netherlands and has subsidiaries in Netherlands. The CEO of the Dutch company is Wilma de Koning.

Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands.

Leids Universitair Medisch Centrum provides medical research, patient care, training, and education. The firm offers fundamental medical and applied clinical research. The company was founded in 1996 and is headquartered in Leiden, the Netherlands.

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek is a scientific research institute and a specialist clinic. The firm’s areas of research are including fundamental, clinical and translational cancer research. The company was founded in 1916 and is headquartered in Amsterdam, Netherlands.

AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.

Multifund BV is an independent investment adviser headquartered in Reeuwijk, Netherlands and was founded in 2002. Multifund manages diversified assets.

Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland.

SomantiX BV develops imaging and therapy of cancer through targeting of tumor blood vessels. The firm offers Somantix’ screening platform which is in combination with the binder generation technologies that allows validation of new therapeutic targets and development of new cancer medicines. The company was founded in 2008 and is headquartered in Utrecht, Netherlands.

Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.

Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands.

Cassini BV manufactures lenses. The private company is based in Delft, Netherlands. The CEO of the Dutch company is Jeroen Cammeraat.

Cassini Technologies BV manufacture of medical instruments and tools. The company was founded by Joris Vogels and Jeroen Cammeraat and is headquartered in The Hague, the Netherlands.

Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.

Dren Bio, Inc. operates as a biotechnology company. It focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents. The company was founded by John Wesley and Nenad Tomasevic in 2019 and is headquartered in San Carlos, CA.

River 2 Renal Corp. develops novel therapies targeting orphan diseases in the renal space. The private company is based in New York, NY.